Fig. 4: Overview of the main peripheral blood-based predictive biomarkers for immune checkpoint inhibitor-based cancer immunotherapy.
From: Cancer immunotherapy: it’s time to better predict patients’ response

AMC absolute monocyte count, CD cluster of differentiation, CRP C-reactive protein, ctDNA circulating tumour DNA, LDH lactate dehydrogenase, MDSC myeloid-derived suppressor cells, NLR neutrophil/lymphocyte ratio, REC relative eosinophil count, RLC relative lymphocyte count, Tex exhausted T cells.